Vycor Medical Inc. Announces Strong 2025 Financial Results and Expanding Clinical Evidence

Vycor Medical Inc. (OTCQB: VYCO), a U.S.-based health‑care equipment and supplies company, reported its financial performance for the year ended December 31, 2025 on March 31, 2026. The company, headquartered in Bohemia, operates through two distinct business units:

  • Vycor Medical – the manufacturer of the ViewSite™ Brain Access System (VBAS), a device designed to aid neurosurgeons in accessing brain tissue with improved precision.
  • NovaVision® – a developmental venture that offers therapy programs intended to restore visual function in patients recovering from stroke or brain injury.

Revenue Growth and Profitability

The Vycor Medical division experienced a notable 18 % rise in revenues compared with 2024, a growth largely driven by expansion into international markets while maintaining a steady increase in U.S. sales. This uptick translated into a modest operating profit of $33,900 for 2025, a sharp turnaround from the $9,145 operating loss recorded in 2024. Non‑GAAP operating profit, which adjusts for certain discretionary items, also showed robust growth, climbing from $81,245 in 2024 to $145,881 in 2025.

Clinical Validation of the ViewSite System

In 2025, Vycor Medical published seven new peer‑reviewed studies focusing on the VBAS. These studies added to a growing body of evidence that now totals 50 peer‑reviewed clinical papers and an additional 14 clinical papers of related nature. The research portfolio demonstrates the device’s international reach, with publications appearing in the United States, the United Kingdom, Japan, and Mexico. The collective data underscore the system’s efficacy and safety profile, reinforcing its value proposition to neurosurgical practitioners worldwide.

Market Context

The company’s market capitalization stands at approximately $3 million USD, with a 52‑week high of $0.50 and a low of $0.051. The current trading price on March 29, 2026, is $0.09 per share. Vycor’s price‑to‑earnings ratio is negative, at –8.77, reflecting the company’s ongoing investment phase and the need for continued capital to fuel product development and market penetration.

Outlook

Vycor Medical’s 2025 results suggest a positive trajectory, marked by revenue expansion, improved profitability, and a solidifying evidence base for its flagship product. The company continues to emphasize its commitment to advancing neurosurgical care through innovative technology and supporting rehabilitation therapies via NovaVision. Investors and stakeholders will be watching closely for the company’s next quarterly disclosures and the progress of its international sales strategy.